FAILED
首站-论文投稿智能助手
典型文献
QAP14 suppresses breast cancer stemness and metastasis via activation of dopamine D1 receptor
文献摘要:
Breast cancer is the second leading cause of cancer-related mortality in women,mainly due to metastasis,which is strongly associated with cancer stemness.Our previous studies showed that the eradication of cancer stem-like cells(CSCs)may be related to the activation of dopamine D1 receptor(D1DR).This study aimed to explicitly demonstrate the target-role of D1DR activation in antimetastatic therapy and to investigate the potential efficacy and the underlying D1 DR-related mechanisms of QAP14,a new oral compound.4T1,MDA-MB-231,and D1 DR-knockout 4T1(4T1-D1DR)cells were selected for in vitro study,while 4T1 and 4T1-D1DR cells were further used to establish a mouse allograft model for in vivo study.Our results showed that D1 DR is abundantly expressed in both 4T1 and MDA-MB-231 cells and that knocking out D1DR in 4T1 cells accelerated migration and invasion in vitro as well as lung metastasis in vivo.QAP14 inhibited colony formation,cell motility,mammosphere formation and CSC frequency,induced CSC apoptosis and D1DR expression,and increased cAMP/cGMP levels.Additionally,QAP14 showed inhibitory effects on tumor growth and lung metastasis with acceptable safety in vivo.Knocking out D1 DR almost completely abolished the efficacy,confirming that QAP14 exhibits its anti-CSC and antimetastatic effects through D1DR activation.The underlying mechanisms involved suppression of the nuclear factor κB(NF-KB)/protein kinase B(Akt)pathway and consequent downregulation of both epithelial-to-mesenchymal transition(EMT)process and cancer stemness.In summary,our findings suggest a potential candidate compound,QAP14,as well as a potential target,D1DR,for metastatic breast cancer therapy.
文献关键词:
作者姓名:
Ling Yong;Ye Yao;Guo-shu Chen;Xiao-xue Yan;Yu-chen Guo;Meng-yi Han;Jun-sheng Xue;Wei-zhe Jian;Tian-yan Zhou
作者机构:
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System,Department of Pharmaceutics,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;Chemical BasicLaboratory,School of Chemistry and Chemical Engineering,Guangzhou University,Guangzhou 510006,China
引用格式:
[1]Ling Yong;Ye Yao;Guo-shu Chen;Xiao-xue Yan;Yu-chen Guo;Meng-yi Han;Jun-sheng Xue;Wei-zhe Jian;Tian-yan Zhou-.QAP14 suppresses breast cancer stemness and metastasis via activation of dopamine D1 receptor)[J].中国药理学报(英文版),2022(04):1001-1012
A类:
QAP14,D1DR,antimetastatic,mammosphere
B类:
suppresses,breast,cancer,stemness,metastasis,via,activation,dopamine,receptor,Breast,second,leading,cause,related,mortality,women,mainly,due,which,strongly,associated,Our,previous,studies,showed,that,eradication,like,cells,CSCs,may,be,This,study,aimed,explicitly,demonstrate,target,role,therapy,investigate,potential,efficacy,underlying,mechanisms,new,oral,compound,4T1,MB,knockout,were,selected,vitro,while,further,used,establish,mouse,allograft,model,vivo,results,abundantly,expressed,both,knocking,accelerated,migration,invasion,well,lung,inhibited,colony,formation,motility,frequency,induced,apoptosis,expression,increased,cAMP,cGMP,levels,Additionally,inhibitory,effects,tumor,growth,acceptable,safety,Knocking,almost,completely,abolished,confirming,exhibits,through,involved,suppression,nuclear,KB,protein,kinase,Akt,pathway,consequent,downregulation,epithelial,mesenchymal,transition,EMT,process,In,summary,our,findings,suggest,candidate
AB值:
0.465991
相似文献
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma
Jingrong Xian;Shiwen Wang;Yanyu Jiang;Lihui Li;Lili Cai;Ping Chen;Yue Liu;Xiaofei Zeng;Guoan Chen;Chen Ding;Robert M.Hoffman;Lijun Jia;Hu Zhao;Yanmei Zhang-Department of Laboratory Medicine,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Research Center on Aging and Medicine,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China;Department of Basic Science of Oncology,College of Basic Medical Sciences,Zhengzhou University,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;School of Medicine,Southern University of Science and Technology,Shenzhen 518055,China;State Key Laboratory of Genetic Engineering,Human Phenome Institute,Institutes of Biomedical Sciences,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200032,China;State Key Laboratory of Cell Differentiation and Regulation,Henan International Joint Laboratory of Pulmonary Fibrosis,Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis,College of Life Science,Institute of Biomedical Science,Henan Normal University,Xinxiang 453007,China;Department of Surgery,University of California,San Diego 92101,USA;Anticancer Inc.,San Diego 92101,USA
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer
Xu Zhang;Na Qin;Jingyi Fan;Chang Zhang;Qi Sun;Yayun Gu;Meng Zhu;Erbao Zhang;Juncheng Dai;Guangfu Jin;Hongxia Ma;Zhibin Hu;Hongbing Shen-Department of Epidemiology,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing 211166,China;Jiangsu Key Lab of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing Medical University,Nanjing 211166,China;Health Management Center,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Gusu School,Nanjing Medical University,Suzhou 215008,China;Research Units of Cohort Study on Cardiovascular Diseases and Cancers,Chinese Academy of Medical Sciences,Beijing 100730,China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。